Fidelis Capital Partners’s iShares Biotechnology ETF IBB Stock Holding History

Fidelis Capital Partners’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.1M	Buy	5,799 +391	+7%	+$67.2K	0.06%	217
2026 Q1	$913K	Buy	5,408 +563	+12%	+$96.3K	0.07%	223
2025 Q4	$818K	Buy	4,845 +30	+0.6%	+$4.87K	0.06%	233
2025 Q3	$695K	Sell	4,815 -237	-5%	-$32.4K	0.05%	250
2025 Q2	$664K	Buy	5,052 +43	+0.9%	+$5.28K	0.06%	228
2025 Q1	$617K	Sell	5,009 -109	-2%	-$14.8K	0.07%	220
2024 Q4	$706K	Sell	5,118 -135	-3%	-$19K	0.07%	207
2024 Q3	$747K	Buy	5,253 +409	+8%	+$59.2K	0.09%	189
2024 Q2	$669K	Buy	4,844 +1,610	+50%	+$215K	0.1%	176
2024 Q1	$444K	Buy	+3,234	New	+$442K	0.07%	224

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.9% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Fidelis Capital Partners's IBB Position: Q2 2026 in Review

Fidelis Capital Partners increased its iShares Biotechnology ETF (IBB) stake by 7.2% in Q2 2026, buying an estimated $67.2K and bringing the position to 5,799 shares worth $1.1M. The position accounts for 0.06% of the portfolio, ranked #217.

Fidelis Capital Partners first reported a position in IBB in Q1 2024 and has held it in 10 quarters since. 960 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

Fidelis Capital Partners held 5,799 shares of iShares Biotechnology ETF worth $1.1M as of Q2 2026.
Fidelis Capital Partners bought 391 iShares Biotechnology ETF shares in Q2 2026, an estimated $67.2K.
iShares Biotechnology ETF made up 0.06% of Fidelis Capital Partners's portfolio in Q2 2026, its #217 holding.
Fidelis Capital Partners first reported a position in iShares Biotechnology ETF in Q1 2024 and has held it in 10 quarters since.
960 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Fidelis Capital Partners's 13F filing for Q2 2026, filed 13 Aug 2026.